The purpose of this study is to determine whether HP184 is effective in the treatment of chronic spinal cord injury (CSCI).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
262
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States
sanofi-aventis administrative Australia & New-Zealand administrative office
Macquarie Park, New South Wales, Australia
Sanofi-Aventis Administrative Office
Berlin, Germany
Sanofi-Aventis Administrative Office
Mumbai, India
Change from baseline in total motor score of American Spinal Injury Association (ASIA) manual motor test at Week 24.
Safety evaluation.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Sanofi-Aventis Administrative Office
Guildford Surrey, United Kingdom